参考文献

2020-10-20

1: Chapple C, Oelke M, Kaplan SA, Scholfield D, Arumi D, Wagg AS. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. Curr Med Res Opin. 2015 Jun;31(6):1201-43. doi: 10.1185/03007995.2015.1032917. Epub 2015 Apr 23. Review. PubMed PMID: 25798911.

2: Hizue M, Ochi Y, Imura M, Yamagami H. [Pharmacological profile and clinical findings of fesoterodine (Toviaz®Tablets )]. Nihon Yakurigaku Zasshi. 2014 Apr;143(4):203-13. Review. Japanese. PubMed PMID: 24717610.

3: Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review. PubMed PMID: 24567280.

4: Morris V, Wagg A. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder? Drug Des Devel Ther. 2014 Jan 9;8:113-9. doi: 10.2147/DDDT.S40032. eCollection 2014. Review. PubMed PMID: 24470751; PubMed Central PMCID: PMC3891639.

5: Rantell A, Cardozo L, Srikrishna S. Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women. Expert Opin Pharmacother. 2014 Feb;15(3):385-93. doi: 10.1517/14656566.2014.875158. Epub 2013 Dec 27. Review. PubMed PMID: 24369895.

6: Mock S, Dmochowski RR. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1659-66. doi: 10.1517/17425255.2013.858118. Epub 2013 Nov 9. Review. PubMed PMID: 24205892.

7: Dell'Utri C, Digesu GA, Bhide A, Khullar V. Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. Int Urogynecol J. 2012 Oct;23(10):1337-44. Epub 2012 Mar 13. Review. PubMed PMID: 22411206.

8: Vella M, Cardozo L. Review of fesoterodine. Expert Opin Drug Saf. 2011 Sep;10(5):805-8. doi: 10.1517/14740338.2011.591377. Epub 2011 Jun 4. Review. PubMed PMID: 21639817.

9: Gupta K, Kaur K, Aulakh BS, Kaushal S. Fesoterodine for overactive bladder: A review of the literature. Curr Ther Res Clin Exp. 2010 Oct;71(5):273-88. doi: 10.1016/j.curtheres.2010.10.003. Review. PubMed PMID: 24688149; PubMed Central PMCID: PMC3969610.

10: Tzefos M, Dolder C, Olin JL. Fesoterodine for the treatment of overactive bladder. Ann Pharmacother. 2009 Dec;43(12):1992-2000. doi: 10.1345/aph.1M308. Epub 2009 Nov 17. Review. PubMed PMID: 19920160.

11: Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. Review. PubMed PMID: 19835561.

12: McKeage K, Keating GM. Fesoterodine. Drugs. 2009;69(6):731-8. doi: 10.2165/00003495-200969060-00006. Review. PubMed PMID: 19405552.

13: Mansfield KJ. Role of fesoterodine in the treatment of overactive bladder. Open Access J Urol. 2009 Dec 17;2:1-9. Review. PubMed PMID: 24198608; PubMed Central PMCID: PMC3818872.

14: Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. doi: 10.1517/14656566.9.10.1787 . Review. PubMed PMID: 18570610.